Eagle-eyed investors might have noticed an omission from a corporate presentation by Axsome Therapeutics, but it does not appear to have damaged optimism genera 15 June 2023
US pharma giant Merck & Co has won out in a lawsuit relating to Bridion (sugammadex), a medication for the reversal of neuromuscular blockade induced by rocuron 14 June 2023
Ahead of a key meeting from the US Food and Drug Administration’s scientific advisory panel, briefing notes reveal a broadly positive view of Eisai and Biogen’s 8 June 2023
Portuguese neuroscience specialist BIAL has announced positive results from the Phase III EPSILON trial of its innovative Parkinson’s disease therapy Ongentys ( 6 June 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.